Good morning (or afternoon) world! Welcome to the latest edition of the Broadway DNA newsletter! In pulling the latest international musical theatre IP headlines, I focus on illuminating post-premiere lifecycles for what commercial theatre creators value: what titles are successful, where, by who, and why? Some of the how, the nuts and bolts of licensing and producing, I dip into in asides mixed in with the news. Natalie-isms, if you will. Whether you're a producer, artist, or simply a musical theatre enthusiast interested in how IP grows global, this bulletin is your ticket to staying informe ..read more

Good morning (or afternoon) world! Welcome to the latest edition of the Broadway DNA newsletter! In pulling the latest international musical theatre IP headlines, I focus on illuminating post-premiere lifecycles for what commercial theatre creators value: what titles are successful, where, by who, and why? Some of the how, the nuts and bolts of licensing and producing, I dip into in asides mixed in with the news. Natalie-isms, if you will. Whether you're a producer, artist, or simply a musical theatre enthusiast interested in how IP grows global, this bulletin is your ticket to staying informe ..read more

It’s been a busy Q1 for Broadway DNA, licensing new work around the world, producing a world premiere new play opening soon, and writing a new publication for the International Theatre Institute out this summer. As I catch up on my to-do list, please excuse this belated review from the exquisite January world premiere of the music theatre piece “Terce: A Practical Breviary.” Thank you for supporting Broadway DNA’s vision to demystify cultural exchange through international producing, licensing, and criticism to empower theatrical discussion around the world. Photo by Maria Baranova of Mel H ..read more

Good morning (or afternoon) world! Welcome to the latest edition of the Broadway DNA newsletter! In pulling the latest international musical theatre IP headlines, I focus on illuminating post-premiere lifecycles for what commercial theatre creators value: what titles are successful, where, by who, and why? Some of the how, the nuts and bolts of licensing and producing, I dip into in asides mixed in with the news. Natalie-isms, if you will. Whether you're a producer, artist, or simply a musical theatre enthusiast interested in how IP grows global, this bulletin is your ticket to staying informe ..read more

Good morning (or afternoon) world! Welcome to the latest edition of the Broadway DNA newsletter! In pulling the latest international musical theatre IP headlines, I focus on illuminating post-premiere lifecycles for what commercial theatre creators value: what titles are successful, where, by who, and why? Some of the how, the nuts and bolts of licensing and producing, I dip into in asides mixed in with the news. Natalie-isms, if you will. Whether you're a producer, artist, or simply a musical theatre enthusiast interested in how IP grows global, this bulletin is your ticket to staying informe ..read more

Good afternoon (or morning) world! Welcome to the latest edition of the Broadway DNA newsletter! In pulling the latest international musical theatre IP headlines, I focus on illuminating post-premiere lifecycles for what commercial theatre creators value: what titles are successful, where, by who, and why? Some of the how, the nuts and bolts of licensing and producing, I dip into in asides mixed in with the news. Natalie-isms, if you will. Whether you're a producer, artist, or simply a musical theatre enthusiast interested in how IP grows global, this bulletin is your ticket to staying informe ..read more

Good morning (or afternoon) world! Welcome to the latest edition of the Broadway DNA newsletter! In pulling the latest international musical theatre IP headlines, I focus on illuminating post-premiere lifecycles for what commercial theatre creators value: what titles are successful, where, by who, and why? Some of the how, the nuts and bolts of licensing and producing, I dip into in asides mixed in with the news. Natalie-isms, if you will. Whether you're a producer, artist, or simply a theatre enthusiast interested in how IP grows global, this bulletin is your ticket to staying informed and ge ..read more

Good morning (or afternoon) world! Welcome to the latest edition of the Broadway DNA newsletter! In pulling the latest international musical theatre IP headlines, I focus on illuminating post-premiere lifecycles for what commercial theatre creators value: what titles are successful, where, by who, and why? Some of the how, the nuts and bolts of licensing and producing, I dip into in asides mixed in with the news. Natalie-isms, if you will. Whether you're a producer, artist, or simply a musical theatre enthusiast interested in how IP grows global, this bulletin is your ticket to staying informe ..read more

Why are you getting this? In addition to The Broadway DNA Blog bi-weekly newsletter of global commercial theatrical news, BDNA is also a proud member of the American and International Theatre Critics Associations, writing reviews supporting globally-minded new shows. Thank you for supporting Broadway DNA’s vision to demystify cultural exchange through international producing, licensing, and criticism to empower theatrical discussion around the world. Video courtesy of PROTOTYPE If you’re not familiar with Wende, the acclaimed Dutch singer-songwriter, theatre-maker, chansonnière, actress, perf ..read more

Why are you getting this? In addition to The Broadway DNA Blog bi-weekly newsletter of global commercial theatrical news, BDNA is also a proud member of the American and International Theatre Critics Associations, writing reviews supporting globally-minded new shows. Thank you for supporting Broadway DNA’s vision to demystify cultural exchange through international producing, licensing, and criticism to empower theatrical discussion around the world. After an excruciating period of outcry and (thankfully) premature grief over the almost-cancellation following a severance by long-time host The ..read more